CD200R-CD28融合蛋白利用抑制性信号增强T细胞功能并治疗小鼠白血病
该研究构建了将CD200R胞质尾替换为CD28信号域的免疫调节融合蛋白(IFP),优化后的CD200R-CD28 IFP转导的T细胞在体外对CD200+白血病细胞增殖和效应功能增强;在播散性白血病过继治疗中,转导的CD8 T细胞比野生型更有效根除致死性疾病,并绕过白介素-2需求;人源等效IFP转导人原代T细胞也增强反应,支持临床转化。
要点
- 优化CD200R-CD28 IFP需二聚化基序和预测的肿瘤-T细胞距离以促进免疫突触定位。
- CD200R-CD28转导的CD8 T细胞在体内更有效根除致死性白血病并绕过IL-2需求。
- 人源等效IFP转导人原代T细胞增强对CD200+白血病细胞的增殖和细胞因子产生。
核心结论
- CD200R-CD28 IFP可 appropriates 抑制性信号以增强T细胞功能,并在小鼠白血病过继治疗中有效。
研究设计与样本
- 研究构建并筛选CD200R-CD28免疫调节融合蛋白(IFP) constructs,在体外和过继治疗小鼠模型及人原代T细胞中验证。
主要发现
- 含二聚化基序和预测肿瘤-T细胞距离的IFP实现最有效共刺激。
- 优化CD200R-CD28 IFP转导的T细胞在体外对CD200+白血病细胞增殖和效应功能增强。
- 过继治疗中CD200R-CD28转导的白血病特异性CD8 T细胞比野生型更有效根除致死性疾病并绕过IL-2给药需求。
- 人源等效IFP转导人原代T细胞增加对CD200+白血病细胞的增殖和细胞因子产生。
关键数值与推荐
- 美国成人急性白血病中最常见的AML 5年生存率为26%。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Acute myeloid leukemia (AML), the most common adult acute leukemia in the United States, has the poorest survival rate, with 26% of patients surviving 5 years. Adoptive immunotherapy with T cells genetically modified to recognize tumors is a promising and evolving treatment option. However, antitumor activity, particularly in the context of progressive leukemia, can be dampened both by limited costimulation and triggering of immunoregulatory checkpoints that attenuate T-cell responses. Expression of CD200 (OX2), a negative regulator of T-cell function that binds CD200 receptor (CD200R), is commonly increased in leukemia and other malignancies and is associated with poor prognosis in leukemia patients. To appropriate and redirect the inhibitory effects of CD200R signaling on transferred CD8+ T cells, we engineered CD200R immunomodulatory fusion proteins (IFPs) with the cytoplasmic tail replaced by the signaling domain of the costimulatory receptor, CD28. An analysis of a panel of CD200R-CD28 IFP constructs revealed that the most effective costimulation was achieved in IFPs containing a dimerizing motif and a predicted tumor-T-cell distance that facilitates localization to the immunological synapse. T cells transduced with the optimized CD200R-CD28 IFPs exhibited enhanced proliferation and effector function in response to CD200+ leukemic cells in vitro. In adoptive therapy of disseminated leukemia, CD200R-CD28-transduced leukemia-specific CD8 T cells eradicated otherwise lethal disease more efficiently than wild-type cells and bypassed the requirement for interleukin-2 administration to sustain in vivo activity. The transduction of human primary T cells with the equivalent human IFPs increased proliferation and cytokine production in response to CD200+ leukemia cells, supporting clinical translation. This trial was registered at www.clinicaltrials.gov as #NCT01640301.
引用
- Oda SK, Daman AW, Garcia NM, et al. A CD200R-CD28 fusion protein appropriates an inhibitory signal to enhance T-cell function and therapy of murine leukemia. Blood. 2017. PMID: 29042364. doi:10.1182/blood-2017-04-777052
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。